Leerink Partnrs Has Weak Estimate for DexCom FY2025 Earnings

DexCom, Inc. (NASDAQ:DXCM) – Stock analysts at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for DexCom in a research report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical device company will post earnings per share of $2.06 for the year, down from their prior estimate of $2.07. The consensus estimate for DexCom’s current full-year earnings is $1.71 per share. Leerink Partnrs also issued estimates for DexCom’s Q4 2025 earnings at $0.66 EPS.

A number of other analysts also recently commented on the stock. Leerink Partners decreased their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Piper Sandler restated an “overweight” rating and set a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. Royal Bank of Canada lowered their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, Wells Fargo & Company boosted their price target on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $104.59.

DexCom Stock Performance

NASDAQ:DXCM opened at $77.94 on Wednesday. The firm’s fifty day simple moving average is $70.94 and its 200-day simple moving average is $88.58. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The stock has a market cap of $30.44 billion, a PE ratio of 46.67, a price-to-earnings-growth ratio of 2.38 and a beta of 1.17. DexCom has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,431 shares of company stock valued at $399,319. Insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

Large investors have recently made changes to their positions in the business. Kennedy Capital Management LLC acquired a new stake in DexCom in the first quarter valued at $1,690,000. B. Riley Wealth Advisors Inc. lifted its holdings in DexCom by 132.0% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 3,766 shares of the medical device company’s stock worth $522,000 after buying an additional 2,143 shares during the last quarter. Tidal Investments LLC increased its holdings in shares of DexCom by 151.8% in the 1st quarter. Tidal Investments LLC now owns 37,439 shares of the medical device company’s stock valued at $5,193,000 after acquiring an additional 22,572 shares during the last quarter. iA Global Asset Management Inc. lifted its stake in DexCom by 2.1% during the first quarter. iA Global Asset Management Inc. now owns 81,003 shares of the medical device company’s stock worth $11,235,000 after purchasing an additional 1,694 shares during the last quarter. Finally, Plato Investment Management Ltd lifted its position in shares of DexCom by 469.4% in the 1st quarter. Plato Investment Management Ltd now owns 13,763 shares of the medical device company’s stock worth $1,909,000 after buying an additional 11,346 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.